Dr. Monk on Bevacizumab in Cervical Cancer

Bradley Monk, MD
Published Online: Tuesday, December 31, 2013
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading